Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in Mycobacterium abscessus
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2314101120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Gregory A Phelps und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Mycobacterium Infections, Nontuberculous, Anti-Infective Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Mycobacterium abscessus ( Mab ), a nontuberculous mycobacterial (NTM) species, is an emerging pathogen with high intrinsic drug resistance. Current standard-of-care therapy results in poor outcomes, demonstrating the urgent need to develop effective antimycobacterial regimens. Through synthetic modification of spectinomycin (SPC), we have identified a distinct structural subclass of N-ethylene linked aminomethyl SPCs (eAmSPCs) that are up to 64-fold more potent against Mab over the parent SPC. Mechanism of action and crystallography studies demonstrate that the eAmSPCs display a mode of ribosomal inhibition consistent with SPC. However, they exert their increased antimicrobial activity through enhanced accumulation, largely by circumventing efflux mechanisms. The N-ethylene linkage within this series plays a critical role in avoiding TetV-mediated efflux, as lead eAmSPC 2593 displays a mere fourfold susceptibility improvement against Mab Δ tetV, in contrast to the 64-fold increase for SPC. Even a minor shortening of the linkage by a single carbon, akin to 1st generation AmSPC 1950, results in a substantial increase in MICs and a 16-fold rise in susceptibility against Mab Δ tetV . These shifts suggest that longer linkages might modify the kinetics of drug expulsion by TetV, ultimately shifting the equilibrium towards heightened intracellular concentrations and enhanced antimicrobial efficacy. Furthermore, lead eAmSPCs were also shown to synergize with various classes of anti- Mab antibiotics and retain activity against clinical isolates and other mycobacterial strains. Encouraging pharmacokinetic profiles coupled with robust efficacy in Mab murine infection models suggest that eAmSPCs hold the potential to be developed into treatments for Mab and other NTM infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105.
- Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38103.
- Institute of Medical Microbiology, University of Zurich, Zurich CH-8006, Switzerland.
- National Reference Center for Mycobacteria, Zurich CH-8006, Switzerland.
- Department of Biological Sciences, University of Illinois at Chicago, Chicago, IL 60607.
- Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163.
ORCID-Profile: Gregory A Phelps, Petra Selchow, Samanthi L Waidyarachchi, Suresh Dharuman, Jiuyu Liu, Michael Meuli, Benjamin Y Killam, Laura A Wilt, Shelby M Anderson, Lei Yang, Bernd Meibohm, Yury S Polikanov, Sven N Hobbie, Erik C Böttger, Peter Sander, Richard E Lee
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- NIH HHS
- NCI NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- HHS | NIH | National Institute of General Medical Sciences
Zitieren
APA
Phelps, G. A., Cheramie, M. N., Fernando, D. M., Selchow, P., Meyer, C. J., Waidyarachchi, S. L., Dharuman, S., Liu, J., Meuli, M., Molin, M. D., Killam, B. Y., Murphy, P. A., Reeve, S. M., Wilt, L. A., Anderson, S. M., Yang, L., Lee, R. B., Temrikar, Z. H., Lukka, P. B., …, & Lee, R. E. (2024). Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in Mycobacterium abscessus. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2314101120
Vancouver
Phelps GA, Cheramie MN, Fernando DM, Selchow P, Meyer CJ, Waidyarachchi SL, et al. Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in Mycobacterium abscessus. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2314101120
BibTeX
@article{Phelps2024,
author = {Phelps, Gregory A and Cheramie, Martin N and Fernando, Dinesh M and Selchow, Petra and Meyer, Christopher J and Waidyarachchi, Samanthi L and Dharuman, Suresh and Liu, Jiuyu and Meuli, Michael and Molin, Michael Dal and Killam, Benjamin Y and Murphy, Patricia A and Reeve, Stephanie M and Wilt, Laura A and Anderson, Shelby M and Yang, Lei and Lee, Robin B and Temrikar, Zaid H and Lukka, Pradeep B and Meibohm, Bernd and Polikanov, Yury S and Hobbie, Sven N and Böttger, Erik C and Sander, Peter and Lee, Richard E},
title = {Development of 2nd generation aminomethyl spectinomycins that overcome native efflux in Mycobacterium abscessus},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2314101120}
}
EUVIMED